Review



modified il26 elisa kit  (Elabscience Biotechnology)


Bioz Verified Symbol Elabscience Biotechnology is a verified supplier
Bioz Manufacturer Symbol Elabscience Biotechnology manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Elabscience Biotechnology modified il26 elisa kit
    Increased IL-26 levels in the serum of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) patients. IL-26 serum levels were quantified by <t>ELISA</t> in 35 HCs (white), 29 axial spondyloarthritis (axSpA) (black), 20 PsA (red) and 15 RA (blue) patients. Preincubation with heat-aggregated bovine IgG and signal amplification with biotinyl-tyramide were applied in order to minimize false results through interfering antibodies . Statistical analysis: mean ± SEM, ** p < 0.01, *** p < 0.001 (one-way ANOVA followed by Dunnett post-test for multiple comparisons).
    Modified Il26 Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/modified il26 elisa kit/product/Elabscience Biotechnology
    Average 90 stars, based on 1 article reviews
    modified il26 elisa kit - by Bioz Stars, 2026-02
    90/100 stars

    Images

    1) Product Images from "Increased interleukin-26 in the peripheral joints of patients with axial spondyloarthritis and psoriatic arthritis, co-localizing with CD68-positive synoviocytes"

    Article Title: Increased interleukin-26 in the peripheral joints of patients with axial spondyloarthritis and psoriatic arthritis, co-localizing with CD68-positive synoviocytes

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2024.1355824

    Increased IL-26 levels in the serum of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) patients. IL-26 serum levels were quantified by ELISA in 35 HCs (white), 29 axial spondyloarthritis (axSpA) (black), 20 PsA (red) and 15 RA (blue) patients. Preincubation with heat-aggregated bovine IgG and signal amplification with biotinyl-tyramide were applied in order to minimize false results through interfering antibodies . Statistical analysis: mean ± SEM, ** p < 0.01, *** p < 0.001 (one-way ANOVA followed by Dunnett post-test for multiple comparisons).
    Figure Legend Snippet: Increased IL-26 levels in the serum of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) patients. IL-26 serum levels were quantified by ELISA in 35 HCs (white), 29 axial spondyloarthritis (axSpA) (black), 20 PsA (red) and 15 RA (blue) patients. Preincubation with heat-aggregated bovine IgG and signal amplification with biotinyl-tyramide were applied in order to minimize false results through interfering antibodies . Statistical analysis: mean ± SEM, ** p < 0.01, *** p < 0.001 (one-way ANOVA followed by Dunnett post-test for multiple comparisons).

    Techniques Used: Enzyme-linked Immunosorbent Assay, Amplification

    IL26 -expressing cells are only slightly increased in circulating CD4 + and CD8 + T cells from patients with axSpA and PsA. (A) Representative flow cytometry plots of total IL26 + CD4 + T cells with the PrimeFlow assay in a PsA patient. RPLA13A represents the positive control for the assay. (B) Percentages of total IL26 + CD4 + T cells (left) and percentages of IL26 + cells of CD26 + CD161 + CD4 + T cells (right) for HCs ( n = 15; white) and axSpA ( n = 15; black) and PsA ( n = 14; red) patients gated from PBMCs stimulated in vitro with PMA and ionomycin in the PrimeFlow assay. (C) Representative flow cytometry plots of total IL-1R1 + Th17 cells in a PsA patient comparing IL-2 stimulation to unstimulated conditions. (D) Percentages of IL-1R1 + Th17 cells (Th17 cells gated as CD4 + CD45RO + CD161 + CCR6 + CCR4 + CXCR3 − ) of CD4 + cells from HCs ( n = 21; white) and axSpA ( n = 22; black), PsA ( n = 14; red), and RA ( n = 13; blue) patients after in vitro stimulation with IL-2 (1,000 IU/ml) overnight (left) and percentages of IL-1R1 + CD26 + CD161 + cells of CD4 + cells (right). (E) Percentages of total IL26 + CD8 + T cells (left) and percentages of IL26 + cells of CD26 + CD161 + CD8 + T cells (right) for HCs ( n = 15; white) and axSpA ( n = 15; black) and PsA ( n = 14; red) patients gated from PBMCs stimulated in vitro with PMA and ionomycin. Statistical analysis: mean ± SEM, * p < 0.05, ** p < 0.01 (one-way ANOVA followed by Dunnett post-test for multiple comparisons).
    Figure Legend Snippet: IL26 -expressing cells are only slightly increased in circulating CD4 + and CD8 + T cells from patients with axSpA and PsA. (A) Representative flow cytometry plots of total IL26 + CD4 + T cells with the PrimeFlow assay in a PsA patient. RPLA13A represents the positive control for the assay. (B) Percentages of total IL26 + CD4 + T cells (left) and percentages of IL26 + cells of CD26 + CD161 + CD4 + T cells (right) for HCs ( n = 15; white) and axSpA ( n = 15; black) and PsA ( n = 14; red) patients gated from PBMCs stimulated in vitro with PMA and ionomycin in the PrimeFlow assay. (C) Representative flow cytometry plots of total IL-1R1 + Th17 cells in a PsA patient comparing IL-2 stimulation to unstimulated conditions. (D) Percentages of IL-1R1 + Th17 cells (Th17 cells gated as CD4 + CD45RO + CD161 + CCR6 + CCR4 + CXCR3 − ) of CD4 + cells from HCs ( n = 21; white) and axSpA ( n = 22; black), PsA ( n = 14; red), and RA ( n = 13; blue) patients after in vitro stimulation with IL-2 (1,000 IU/ml) overnight (left) and percentages of IL-1R1 + CD26 + CD161 + cells of CD4 + cells (right). (E) Percentages of total IL26 + CD8 + T cells (left) and percentages of IL26 + cells of CD26 + CD161 + CD8 + T cells (right) for HCs ( n = 15; white) and axSpA ( n = 15; black) and PsA ( n = 14; red) patients gated from PBMCs stimulated in vitro with PMA and ionomycin. Statistical analysis: mean ± SEM, * p < 0.05, ** p < 0.01 (one-way ANOVA followed by Dunnett post-test for multiple comparisons).

    Techniques Used: Expressing, Flow Cytometry, Positive Control, In Vitro

    CD4 + T cells from axSpA patients are prone to IL26 expression under typical Th17-favoring conditions in vitro . (A) Total CD4 + T cells from HCs ( n = 20; white) and axSpA ( n = 19; black), PsA ( n = 18; red), and RA n = 13; blue) patients were incubated with different Th17-favoring cytokine combinations in vitro for 6 days, and the expression of IL26 and IL17A was analyzed by qPCR in triplicates. Expression was normalized to two control genes ( ACT and RPL13A ) and is shown as fold expression in relation to basal stimulation with IL-2 only. (B) CD4 + T cells from the same cohort as in (A) were stimulated with IL-2, IL-1β, and IL-23 for 6 days in vitro , and fold expression (triplicates each) of the respective genes is shown in relation to HCs after normalizations for ACT and RLP13A . Statistical analysis: mean ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001 [ (A) repeated-measures ANOVA and (B) one-way ANOVA followed by Dunnett post-test for multiple comparisons].
    Figure Legend Snippet: CD4 + T cells from axSpA patients are prone to IL26 expression under typical Th17-favoring conditions in vitro . (A) Total CD4 + T cells from HCs ( n = 20; white) and axSpA ( n = 19; black), PsA ( n = 18; red), and RA n = 13; blue) patients were incubated with different Th17-favoring cytokine combinations in vitro for 6 days, and the expression of IL26 and IL17A was analyzed by qPCR in triplicates. Expression was normalized to two control genes ( ACT and RPL13A ) and is shown as fold expression in relation to basal stimulation with IL-2 only. (B) CD4 + T cells from the same cohort as in (A) were stimulated with IL-2, IL-1β, and IL-23 for 6 days in vitro , and fold expression (triplicates each) of the respective genes is shown in relation to HCs after normalizations for ACT and RLP13A . Statistical analysis: mean ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001 [ (A) repeated-measures ANOVA and (B) one-way ANOVA followed by Dunnett post-test for multiple comparisons].

    Techniques Used: Expressing, In Vitro, Incubation, Control



    Similar Products

    modified il26 elisa kit  (Elabscience Biotechnology)
    90
    Elabscience Biotechnology modified il26 elisa kit
    Increased IL-26 levels in the serum of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) patients. IL-26 serum levels were quantified by <t>ELISA</t> in 35 HCs (white), 29 axial spondyloarthritis (axSpA) (black), 20 PsA (red) and 15 RA (blue) patients. Preincubation with heat-aggregated bovine IgG and signal amplification with biotinyl-tyramide were applied in order to minimize false results through interfering antibodies . Statistical analysis: mean ± SEM, ** p < 0.01, *** p < 0.001 (one-way ANOVA followed by Dunnett post-test for multiple comparisons).
    Modified Il26 Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/modified il26 elisa kit/product/Elabscience Biotechnology
    Average 90 stars, based on 1 article reviews
    modified il26 elisa kit - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Increased IL-26 levels in the serum of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) patients. IL-26 serum levels were quantified by ELISA in 35 HCs (white), 29 axial spondyloarthritis (axSpA) (black), 20 PsA (red) and 15 RA (blue) patients. Preincubation with heat-aggregated bovine IgG and signal amplification with biotinyl-tyramide were applied in order to minimize false results through interfering antibodies . Statistical analysis: mean ± SEM, ** p < 0.01, *** p < 0.001 (one-way ANOVA followed by Dunnett post-test for multiple comparisons).

    Journal: Frontiers in Immunology

    Article Title: Increased interleukin-26 in the peripheral joints of patients with axial spondyloarthritis and psoriatic arthritis, co-localizing with CD68-positive synoviocytes

    doi: 10.3389/fimmu.2024.1355824

    Figure Lengend Snippet: Increased IL-26 levels in the serum of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) patients. IL-26 serum levels were quantified by ELISA in 35 HCs (white), 29 axial spondyloarthritis (axSpA) (black), 20 PsA (red) and 15 RA (blue) patients. Preincubation with heat-aggregated bovine IgG and signal amplification with biotinyl-tyramide were applied in order to minimize false results through interfering antibodies . Statistical analysis: mean ± SEM, ** p < 0.01, *** p < 0.001 (one-way ANOVA followed by Dunnett post-test for multiple comparisons).

    Article Snippet: Serum levels of IL26 were analyzed with a modified IL26 ELISA kit (Elabscience, Wuhan, China).

    Techniques: Enzyme-linked Immunosorbent Assay, Amplification

    IL26 -expressing cells are only slightly increased in circulating CD4 + and CD8 + T cells from patients with axSpA and PsA. (A) Representative flow cytometry plots of total IL26 + CD4 + T cells with the PrimeFlow assay in a PsA patient. RPLA13A represents the positive control for the assay. (B) Percentages of total IL26 + CD4 + T cells (left) and percentages of IL26 + cells of CD26 + CD161 + CD4 + T cells (right) for HCs ( n = 15; white) and axSpA ( n = 15; black) and PsA ( n = 14; red) patients gated from PBMCs stimulated in vitro with PMA and ionomycin in the PrimeFlow assay. (C) Representative flow cytometry plots of total IL-1R1 + Th17 cells in a PsA patient comparing IL-2 stimulation to unstimulated conditions. (D) Percentages of IL-1R1 + Th17 cells (Th17 cells gated as CD4 + CD45RO + CD161 + CCR6 + CCR4 + CXCR3 − ) of CD4 + cells from HCs ( n = 21; white) and axSpA ( n = 22; black), PsA ( n = 14; red), and RA ( n = 13; blue) patients after in vitro stimulation with IL-2 (1,000 IU/ml) overnight (left) and percentages of IL-1R1 + CD26 + CD161 + cells of CD4 + cells (right). (E) Percentages of total IL26 + CD8 + T cells (left) and percentages of IL26 + cells of CD26 + CD161 + CD8 + T cells (right) for HCs ( n = 15; white) and axSpA ( n = 15; black) and PsA ( n = 14; red) patients gated from PBMCs stimulated in vitro with PMA and ionomycin. Statistical analysis: mean ± SEM, * p < 0.05, ** p < 0.01 (one-way ANOVA followed by Dunnett post-test for multiple comparisons).

    Journal: Frontiers in Immunology

    Article Title: Increased interleukin-26 in the peripheral joints of patients with axial spondyloarthritis and psoriatic arthritis, co-localizing with CD68-positive synoviocytes

    doi: 10.3389/fimmu.2024.1355824

    Figure Lengend Snippet: IL26 -expressing cells are only slightly increased in circulating CD4 + and CD8 + T cells from patients with axSpA and PsA. (A) Representative flow cytometry plots of total IL26 + CD4 + T cells with the PrimeFlow assay in a PsA patient. RPLA13A represents the positive control for the assay. (B) Percentages of total IL26 + CD4 + T cells (left) and percentages of IL26 + cells of CD26 + CD161 + CD4 + T cells (right) for HCs ( n = 15; white) and axSpA ( n = 15; black) and PsA ( n = 14; red) patients gated from PBMCs stimulated in vitro with PMA and ionomycin in the PrimeFlow assay. (C) Representative flow cytometry plots of total IL-1R1 + Th17 cells in a PsA patient comparing IL-2 stimulation to unstimulated conditions. (D) Percentages of IL-1R1 + Th17 cells (Th17 cells gated as CD4 + CD45RO + CD161 + CCR6 + CCR4 + CXCR3 − ) of CD4 + cells from HCs ( n = 21; white) and axSpA ( n = 22; black), PsA ( n = 14; red), and RA ( n = 13; blue) patients after in vitro stimulation with IL-2 (1,000 IU/ml) overnight (left) and percentages of IL-1R1 + CD26 + CD161 + cells of CD4 + cells (right). (E) Percentages of total IL26 + CD8 + T cells (left) and percentages of IL26 + cells of CD26 + CD161 + CD8 + T cells (right) for HCs ( n = 15; white) and axSpA ( n = 15; black) and PsA ( n = 14; red) patients gated from PBMCs stimulated in vitro with PMA and ionomycin. Statistical analysis: mean ± SEM, * p < 0.05, ** p < 0.01 (one-way ANOVA followed by Dunnett post-test for multiple comparisons).

    Article Snippet: Serum levels of IL26 were analyzed with a modified IL26 ELISA kit (Elabscience, Wuhan, China).

    Techniques: Expressing, Flow Cytometry, Positive Control, In Vitro

    CD4 + T cells from axSpA patients are prone to IL26 expression under typical Th17-favoring conditions in vitro . (A) Total CD4 + T cells from HCs ( n = 20; white) and axSpA ( n = 19; black), PsA ( n = 18; red), and RA n = 13; blue) patients were incubated with different Th17-favoring cytokine combinations in vitro for 6 days, and the expression of IL26 and IL17A was analyzed by qPCR in triplicates. Expression was normalized to two control genes ( ACT and RPL13A ) and is shown as fold expression in relation to basal stimulation with IL-2 only. (B) CD4 + T cells from the same cohort as in (A) were stimulated with IL-2, IL-1β, and IL-23 for 6 days in vitro , and fold expression (triplicates each) of the respective genes is shown in relation to HCs after normalizations for ACT and RLP13A . Statistical analysis: mean ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001 [ (A) repeated-measures ANOVA and (B) one-way ANOVA followed by Dunnett post-test for multiple comparisons].

    Journal: Frontiers in Immunology

    Article Title: Increased interleukin-26 in the peripheral joints of patients with axial spondyloarthritis and psoriatic arthritis, co-localizing with CD68-positive synoviocytes

    doi: 10.3389/fimmu.2024.1355824

    Figure Lengend Snippet: CD4 + T cells from axSpA patients are prone to IL26 expression under typical Th17-favoring conditions in vitro . (A) Total CD4 + T cells from HCs ( n = 20; white) and axSpA ( n = 19; black), PsA ( n = 18; red), and RA n = 13; blue) patients were incubated with different Th17-favoring cytokine combinations in vitro for 6 days, and the expression of IL26 and IL17A was analyzed by qPCR in triplicates. Expression was normalized to two control genes ( ACT and RPL13A ) and is shown as fold expression in relation to basal stimulation with IL-2 only. (B) CD4 + T cells from the same cohort as in (A) were stimulated with IL-2, IL-1β, and IL-23 for 6 days in vitro , and fold expression (triplicates each) of the respective genes is shown in relation to HCs after normalizations for ACT and RLP13A . Statistical analysis: mean ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001 [ (A) repeated-measures ANOVA and (B) one-way ANOVA followed by Dunnett post-test for multiple comparisons].

    Article Snippet: Serum levels of IL26 were analyzed with a modified IL26 ELISA kit (Elabscience, Wuhan, China).

    Techniques: Expressing, In Vitro, Incubation, Control